• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Jim Cramer Calls Nutanix 'The Perfect Enterprise Software Company For The Moment'

    5/7/24 8:33:34 AM ET
    $AEM
    $ALT
    $CVI
    $NTNX
    Precious Metals
    Basic Materials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEM alert in real time by email

    On CNBC's “Mad Money Lightning Round,” Jim Cramer described Quanta Services (NYSE:PWR) as “so good” and a “terrific” company.

    On May 2, Quanta Services posted better-than-expected quarterly results.

    “I think that the cycle could be turning against them,” Cramer said about CVR Energy, Inc. (NYSE:CVI). “Let's be very careful, CVR.”

    On April 29, CVR Energy posted weaker-than-expected results for its first quarter.

    Nutanix, Inc. (NASDAQ:NTNX) is a “perfect enterprise software company for the moment because it's cloud enterprise software, and that's what people want,” Cramer said. “It's very expensive, but it's going to keep going higher.”

    San Jose, California-based Nutanix is expected to report its financial results for the third quarter of fiscal year 2024, after the closing bell on Wednesday, May 29.

    When asked about Agnico Eagle Mines (NYSE:AEM), Cramer said he likes gold. On April 25, Agnico Eagle Mines reported better-than-expected first-quarter financial results.

    Altimmune, Inc. (NASDAQ:ALT) is “not bad that it's spec,” Cramer said. “I'm literally saying it's one of those situations because it's not making any money and losing a lot of money, that you have to expect the fact that if one of its drugs fails, it is going to get hit.”

    Altimmune is scheduled to report its first quarter 2024 financial results on Thursday, May 9.

    Price Action:

    • Agnico Eagle Mines shares gained 1.7% to settle at $66.13 on Monday.
    • Nutanix shares gained 4.3% to close at $64.93.
    • Altimmune shares gained 0.8% to settle at $7.36.
    • CVR Energy shares rose 0.4% to close at $29.61 on Monday.
    • Quanta Services shares gained 5.1% to settle at $269.50 on Monday.

    Read Next: Investor Optimism Decreases Slightly, But Dow Records Gains For 4th Day

    Photo: Shutterstock

    Get the next $AEM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEM
    $ALT
    $CVI
    $NTNX

    CompanyDatePrice TargetRatingAnalyst
    Agnico Eagle Mines Limited
    $AEM
    1/29/2026$248.00Neutral
    Analyst
    Altimmune Inc.
    $ALT
    1/28/2026$20.00Overweight
    Barclays
    Quanta Services Inc.
    $PWR
    1/23/2026$520.00Overweight
    Cantor Fitzgerald
    Nutanix Inc.
    $NTNX
    1/15/2026$53.00Overweight → Equal Weight
    Barclays
    Nutanix Inc.
    $NTNX
    1/12/2026Overweight → Equal-Weight
    Morgan Stanley
    Quanta Services Inc.
    $PWR
    1/9/2026Neutral → Buy
    Seaport Research Partners
    Quanta Services Inc.
    $PWR
    12/8/2025$515.00Neutral → Overweight
    Analyst
    Nutanix Inc.
    $NTNX
    11/26/2025$80.00 → $65.00Buy
    Needham
    More analyst ratings

    $AEM
    $ALT
    $CVI
    $NTNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QUANTA SERVICES REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Full-Year 2026 Guidance Reflects Double-Digit Growth in Revenues, Net Income and Adjusted EBITDAFull-Year 2026 Guidance Range Reflects Opportunity to Deliver Over 20% EPS GrowthExpect to Achieve Record Backlog in 2026Fourth Quarter 2025 Results Include:Consolidated Revenues of $7.84 Billion*GAAP Diluted EPS of $2.08* and Adjusted Diluted EPS of $3.16*Net Income Attributable to Common Stock of $315.5 Million*Adjusted EBITDA of $845.3 Million*Cash Flow From Operations of $1.13 Billion* and Free Cash Flow of $946.4 Million*Year-End Remaining Performance Obligations (RPO) of $23.76 Billion* and Total Backlog of $43.98 Billion*Year-End Electric Infrastructure Solutions Segment RPO and Total Backl

    2/19/26 6:55:00 AM ET
    $PWR
    Engineering & Construction
    Industrials

    CVR Energy Reports Fourth Quarter and Full-Year 2025 Results

    Net loss attributable to CVR Energy stockholders of $110 million for fourth quarter 2025, and net income attributable to CVR Energy stockholders of $27 million for full-year 2025 EBITDA and Adjusted EBITDA of $51 million and $91 million, respectively, for fourth quarter 2025, and $591 million and $393 million, respectively, for full-year 2025 Completed the reversion of the Renewable Diesel Unit ("RDU") at the Wynnewood Refinery back to hydrocarbon processing service in December 2025 Prepaid $75 million in principal of the Term Loan in December 2025 CVR Partners announced a fourth quarter 2025 cash distribution of 37 cents per common unit CVR Energy, Inc. ("CVR Energy" or the

    2/18/26 4:26:00 PM ET
    $CVI
    Integrated oil Companies
    Energy

    AGNICO EAGLE ANNOUNCES ADDITIONAL INVESTMENT IN MAPLE GOLD MINES LTD.

    Stock Symbol:  AEM (NYSE and TSX)TORONTO, Feb. 17, 2026 /CNW/ - Agnico Eagle Mines Limited (NYSE:AEM) (TSX:AEM) ("Agnico Eagle") announced today that it has acquired 662,780 common shares ("Common Shares") of Maple Gold Mines Ltd. (TSXV:MGM) ("Maple") at C$2.45 per Common Share (the "Share Purchases") for total consideration of C$1,623,811 from several sellers that participated in an offering of flow-through Common Shares undertaken by Maple immediately prior to the Share Purchases.On September 9, 2025, Agnico Eagle filed an early warning report disclosing that it owned Common Shares and common share purchase warrants (each, a "Warrant") representing approximately 15.38% and 16.32% of the th

    2/17/26 5:45:00 PM ET
    $AEM
    Precious Metals
    Basic Materials

    $AEM
    $ALT
    $CVI
    $NTNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pisano Wayne bought $20,410 worth of shares (5,000 units at $4.08), increasing direct ownership by 59% to 13,498 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    1/9/26 4:10:05 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sohn Catherine A. bought $2,118 worth of shares (500 units at $4.24), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    1/5/26 4:05:39 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jorkasky Diane bought $2,003 worth of shares (527 units at $3.80) (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    12/29/25 4:10:05 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEM
    $ALT
    $CVI
    $NTNX
    SEC Filings

    View All

    $AEM
    $ALT
    $CVI
    $NTNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 6-K filed by Agnico Eagle Mines Limited

    6-K - AGNICO EAGLE MINES LTD (0000002809) (Filer)

    2/19/26 11:19:40 AM ET
    $AEM
    Precious Metals
    Basic Materials

    SEC Form 10-K filed by Quanta Services Inc.

    10-K - QUANTA SERVICES, INC. (0001050915) (Filer)

    2/19/26 9:58:03 AM ET
    $PWR
    Engineering & Construction
    Industrials

    Quanta Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - QUANTA SERVICES, INC. (0001050915) (Filer)

    2/19/26 6:58:17 AM ET
    $PWR
    Engineering & Construction
    Industrials

    SEC Form 4 filed by EVP & Chief Commercial Officer Capps J. Travis Jr.

    4 - CVR ENERGY INC (0001376139) (Issuer)

    2/20/26 4:15:32 PM ET
    $CVI
    Integrated oil Companies
    Energy

    Chief Scientific Officer Roberts M Scot converted options into 17,050 shares, covered exercise/tax liability with 5,188 shares and was granted 5,567 shares, increasing direct ownership by 18% to 112,824 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    2/3/26 4:15:42 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Garg Vipin K converted options into 26,775 shares, covered exercise/tax liability with 11,632 shares and was granted 6,926 shares, increasing direct ownership by 5% to 424,519 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    2/2/26 4:15:29 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEM
    $ALT
    $CVI
    $NTNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Agnico-Eagle Mines with a new price target

    Analyst initiated coverage of Agnico-Eagle Mines with a rating of Neutral and set a new price target of $248.00

    1/29/26 7:00:38 AM ET
    $AEM
    Precious Metals
    Basic Materials

    Barclays initiated coverage on Altimmune with a new price target

    Barclays initiated coverage of Altimmune with a rating of Overweight and set a new price target of $20.00

    1/28/26 7:15:18 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Quanta Services with a new price target

    Cantor Fitzgerald initiated coverage of Quanta Services with a rating of Overweight and set a new price target of $520.00

    1/23/26 8:20:46 AM ET
    $PWR
    Engineering & Construction
    Industrials

    $AEM
    $ALT
    $CVI
    $NTNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by CVR Energy Inc.

    SC 13D/A - CVR ENERGY INC (0001376139) (Subject)

    1/7/25 6:12:47 AM ET
    $CVI
    Integrated oil Companies
    Energy

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    11/14/24 11:58:56 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nutanix Inc.

    SC 13G/A - Nutanix, Inc. (0001618732) (Subject)

    11/13/24 3:31:01 PM ET
    $NTNX
    Computer Software: Prepackaged Software
    Technology

    $AEM
    $ALT
    $CVI
    $NTNX
    Financials

    Live finance-specific insights

    View All

    QUANTA SERVICES REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Full-Year 2026 Guidance Reflects Double-Digit Growth in Revenues, Net Income and Adjusted EBITDAFull-Year 2026 Guidance Range Reflects Opportunity to Deliver Over 20% EPS GrowthExpect to Achieve Record Backlog in 2026Fourth Quarter 2025 Results Include:Consolidated Revenues of $7.84 Billion*GAAP Diluted EPS of $2.08* and Adjusted Diluted EPS of $3.16*Net Income Attributable to Common Stock of $315.5 Million*Adjusted EBITDA of $845.3 Million*Cash Flow From Operations of $1.13 Billion* and Free Cash Flow of $946.4 Million*Year-End Remaining Performance Obligations (RPO) of $23.76 Billion* and Total Backlog of $43.98 Billion*Year-End Electric Infrastructure Solutions Segment RPO and Total Backl

    2/19/26 6:55:00 AM ET
    $PWR
    Engineering & Construction
    Industrials

    CVR Energy Reports Fourth Quarter and Full-Year 2025 Results

    Net loss attributable to CVR Energy stockholders of $110 million for fourth quarter 2025, and net income attributable to CVR Energy stockholders of $27 million for full-year 2025 EBITDA and Adjusted EBITDA of $51 million and $91 million, respectively, for fourth quarter 2025, and $591 million and $393 million, respectively, for full-year 2025 Completed the reversion of the Renewable Diesel Unit ("RDU") at the Wynnewood Refinery back to hydrocarbon processing service in December 2025 Prepaid $75 million in principal of the Term Loan in December 2025 CVR Partners announced a fourth quarter 2025 cash distribution of 37 cents per common unit CVR Energy, Inc. ("CVR Energy" or the

    2/18/26 4:26:00 PM ET
    $CVI
    Integrated oil Companies
    Energy

    AGNICO EAGLE PROVIDES AN UPDATE ON 2025 EXPLORATION RESULTS AND 2026 EXPLORATION PLANS - YEAR OVER YEAR MINERAL RESERVES INCREASE 2% TO 55.4 MOZ; INDICATED MINERAL RESOURCES INCREASE 10% TO 47.1 MOZ AND INFERRED MINERAL RESOURCES INCREASE 15% TO 41.8 MOZ

    Stock Symbol: AEM (NYSE and TSX) (All amounts expressed in U.S. dollars unless otherwise noted) TORONTO, Feb. 12, 2026 /PRNewswire/ - Agnico Eagle Mines Limited (NYSE:AEM) (TSX:AEM) ("Agnico Eagle" or the "Company") is pleased to provide an update on year-end 2025 mineral reserves and mineral resources, exploration activities at mine sites and select advanced projects in 2025, and the Company's exploration plans and guidance for 2026. The Company's exploration focus remains on extending mine life at existing operations, testing near-mine opportunities and advancing key value driver projects. "I would like to congratulate our exploration team for their performance in 2025 in terms of safety,

    2/12/26 5:30:00 PM ET
    $AEM
    Precious Metals
    Basic Materials

    $AEM
    $ALT
    $CVI
    $NTNX
    Leadership Updates

    Live Leadership Updates

    View All

    Altimmune Announces CEO Transition and Succession Plan

    Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company's President and Chief Executive Officer effective January 1, 2026. Altimmune's Chairman of the Board, Jerry Durso, will assume the role of President and Chief Executive Officer and retain his position as Chairman. To facilitat

    12/1/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

    GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeutic areas, including metabolic disease, hepatology, cardiovascular and addiction medicine. During her career, she has led multiple product launches, built successful commercial franchises

    9/15/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care